Grapheton, Inc.

Grapheton’s main products are next generation carbon-based implantable devices with integrated on-chip self-powering energy sources. Equally importantly, Grapheton’s probes can simultaneously read both the electrical and chemical signals that regulate processes throughout the body. Grapheton continues to build a rich portfolio of forward-looking solutions, proprietary technologies, and intellectual property in these cutting-edge areas. Bioelectronics, the treatment of disease, injury and disability using electronic devices, is a huge and growing market. A much more natural fit with biological processes, our products are made of a homogenous non-granular carbon material that could stay implanted in the human body for several decades without degradation or damage to the underlying tissues. The sensitivity and selectivity of Grapheton’s probes exceed state-of-the-art as supported by peer-reviewed scientific publications. Over the past fifteen years, the underlying technology of Grapheton was developed at and licensed from NanoFAB.SDSU, which is part of the Center for Neurotechnology (CNT) Engineering Research Center, a collaboration between University of Washington, MIT and San Diego State University. As our technology comes out of the laboratory environment and enters clinical applications, Grapheton’s technology has the potential to revolutionize human bioelectronic implants by creating lifelong treatments that continuously adjust through closed-loop monitoring of the body’s electrical and chemical environment.